Cargando…

Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis

Immunotherapy has yielded impressive results, but only for a minority of patients with cancer. Therefore, new approaches that potentiate immunotherapy are a pressing medical need. Ferroptosis is a newly described type of programmed cell death driven by iron-dependent phospholipid peroxidation via Fe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-de-Angulo, Ane, Bilbao-Asensio, Marc, Cronin, James, Evans, Stephen J., Clift, Martin J.D., Llop, Jordi, Feiner, Irene V.J., Beadman, Rhiannon, Bascarán, Kepa Zamacola, Mareque-Rivas, Juan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490994/
https://www.ncbi.nlm.nih.gov/pubmed/32919370
http://dx.doi.org/10.1016/j.isci.2020.101499
_version_ 1783582131454214144
author Ruiz-de-Angulo, Ane
Bilbao-Asensio, Marc
Cronin, James
Evans, Stephen J.
Clift, Martin J.D.
Llop, Jordi
Feiner, Irene V.J.
Beadman, Rhiannon
Bascarán, Kepa Zamacola
Mareque-Rivas, Juan C.
author_facet Ruiz-de-Angulo, Ane
Bilbao-Asensio, Marc
Cronin, James
Evans, Stephen J.
Clift, Martin J.D.
Llop, Jordi
Feiner, Irene V.J.
Beadman, Rhiannon
Bascarán, Kepa Zamacola
Mareque-Rivas, Juan C.
author_sort Ruiz-de-Angulo, Ane
collection PubMed
description Immunotherapy has yielded impressive results, but only for a minority of patients with cancer. Therefore, new approaches that potentiate immunotherapy are a pressing medical need. Ferroptosis is a newly described type of programmed cell death driven by iron-dependent phospholipid peroxidation via Fenton chemistry. Here, we developed iron oxide-loaded nanovaccines (IONVs), which, chemically programmed to integrate iron catalysis, drug delivery, and tracking exploiting the characteristics of the tumor microenvironment (TME), improves immunotherapy and activation of ferroptosis. The IONVs trigger danger signals and use molecular disassembly and reversible covalent bonds for targeted antigen delivery and improved immunostimulatory capacity and catalytic iron for targeting tumor cell ferroptosis. IONV- and antibody-mediated TME modulation interfaced with imaging was important toward achieving complete eradication of aggressive and established tumors, eliciting long-lived protective antitumor immunity with no toxicities. This work establishes the feasibility of using nanoparticle iron catalytic activity as a versatile and effective feature for enhancing immunotherapy.
format Online
Article
Text
id pubmed-7490994
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-74909942020-09-21 Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis Ruiz-de-Angulo, Ane Bilbao-Asensio, Marc Cronin, James Evans, Stephen J. Clift, Martin J.D. Llop, Jordi Feiner, Irene V.J. Beadman, Rhiannon Bascarán, Kepa Zamacola Mareque-Rivas, Juan C. iScience Article Immunotherapy has yielded impressive results, but only for a minority of patients with cancer. Therefore, new approaches that potentiate immunotherapy are a pressing medical need. Ferroptosis is a newly described type of programmed cell death driven by iron-dependent phospholipid peroxidation via Fenton chemistry. Here, we developed iron oxide-loaded nanovaccines (IONVs), which, chemically programmed to integrate iron catalysis, drug delivery, and tracking exploiting the characteristics of the tumor microenvironment (TME), improves immunotherapy and activation of ferroptosis. The IONVs trigger danger signals and use molecular disassembly and reversible covalent bonds for targeted antigen delivery and improved immunostimulatory capacity and catalytic iron for targeting tumor cell ferroptosis. IONV- and antibody-mediated TME modulation interfaced with imaging was important toward achieving complete eradication of aggressive and established tumors, eliciting long-lived protective antitumor immunity with no toxicities. This work establishes the feasibility of using nanoparticle iron catalytic activity as a versatile and effective feature for enhancing immunotherapy. Elsevier 2020-08-26 /pmc/articles/PMC7490994/ /pubmed/32919370 http://dx.doi.org/10.1016/j.isci.2020.101499 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Ruiz-de-Angulo, Ane
Bilbao-Asensio, Marc
Cronin, James
Evans, Stephen J.
Clift, Martin J.D.
Llop, Jordi
Feiner, Irene V.J.
Beadman, Rhiannon
Bascarán, Kepa Zamacola
Mareque-Rivas, Juan C.
Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis
title Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis
title_full Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis
title_fullStr Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis
title_full_unstemmed Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis
title_short Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis
title_sort chemically programmed vaccines: iron catalysis in nanoparticles enhances combination immunotherapy and immunotherapy-promoted tumor ferroptosis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490994/
https://www.ncbi.nlm.nih.gov/pubmed/32919370
http://dx.doi.org/10.1016/j.isci.2020.101499
work_keys_str_mv AT ruizdeanguloane chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis
AT bilbaoasensiomarc chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis
AT croninjames chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis
AT evansstephenj chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis
AT cliftmartinjd chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis
AT llopjordi chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis
AT feinerirenevj chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis
AT beadmanrhiannon chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis
AT bascarankepazamacola chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis
AT marequerivasjuanc chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis